450
Views
13
CrossRef citations to date
0
Altmetric
Case Reports

Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis

, , , , &
Pages 677-680 | Received 20 Aug 2012, Accepted 22 Nov 2012, Published online: 11 Feb 2014

References

  • Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36: 88–98
  • Bartels CM, Bridqes AJ. Rheumatoid vasculitis: vanishing menace or target for new treatments?. Curr Rheumatol Rep. 2010;12: 414–419
  • Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol. 2006;18: 277–281
  • Sumida K, Ubara Y, Takemoto F, Takaichi K. Successful treatment with humanized anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol. 2011;29: S133
  • Ozaki Y, Tanaka A, Shimamoto K, Amuro H, Kawakami K, Son Y, Ito T, Wada T, Nomura S. A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment. Mod Rheumatol. 2011;21: 302–304
  • Nomeir AM, Turner R, Watts E, Smith D, West G, Edmonds J. Cardiac involvement in rheumatoid arthritis. Ann Intern Med. 1973;79: 800–806.
  • Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford). 2006;45(Suppl 4): iv4–iv7
  • Volskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case control study. Ann Rheum Dis. 1996;55: 190–192
  • Puéchal X, Miceli-Richard C, Meiiad O, Lafforque P, Marcelli C, Solau-Gervais E, Steinfeld S, Villoutreix C, Trèves R, Mariette X Club Rheumatismes et inflammation (CRI). Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis. 2008;67: 880–884
  • Gabay C, Emery P, Vollenhoven R, Dikranian A, Alten R, Klearman M et al. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial. Ann Rheum Dis. 2012;71(S3): 152
  • Iwamoto M, Honma S, Asano Y, Minota S. Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis. Rheumatol Int. 2011;31: 559–560
  • Hattori Y, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M et al. Tocilizumab improves cardiac disease in a hemodialysis patients with AA amyloidosis secondary to rheumatoid arthritis. Amyloid. 2012;19: 37–40
  • Shikama N, Terano T, Hirai A. A case of rheumatoid pericarditis with high concentrations of interleukin-6 in pericardial fluid. Heart. 2000;83: 711–712

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.